RAVIMIAMET

Hinnangu kokkuvõte

04.03.2013 anti müügiluba GlaxoSmithKline Dungarvan Limited ravimile Voltaren Emulgel, 23.2 mg/g geel.

Müügiluba taotleti riikliku protseduuri kaudu.

Tegemist on käsimüügiravimiga.

Voltaren Emulgel geeli kasutatakse täiskasvanutel ja üle 14-aastastel noorukitel valu, põletiku ja turse paikseks leevendamiseks pehmete kudede kahjustuste korral (nt lihas-ja liigestraumade (nihestused, nikastused, muljumised, seljavalu, sporditraumad) korral, kõõlusepõletik, küünarvarre või põlve turse).

Ravimi Voltaren Emulgel toimeaine on diklofenakdietüülamiin. 1 g geeli sisaldab 23,2 mg diklofenakdietüülamiini, mis vastab 20 mg diklofenaknaatriumile. Voltaren Emulgel kuulub ravimite rühma, mida nimetatakse mittesteroidsed põletikuvastased ained paikseks kasutamiseks.

Ravimile anti müügiluba, kuna Voltaren Emulgel`i kasutamisest oodatav kasu ületab võimalikud riskid.

Avalik hinnanguaruanne on leitav järgnevatelt lehekülgedelt.

Public Assessment Report

Scientific discussion

VOLTAREN EMULGEL
Diclofenac diethylamine

Date: 15.12.2018

This module reflects the scientific discussion for the approval of Voltaren Emulgel. The procedure was finalised at 04.03.2013. For information on changes after this date please refer to the module 'Update'.

I. INTRODUCTION

Based on the review of the quality, safety and efficacy data, Estonia has granted a marketing authorisation for Voltaren Emulgel, 23.2 mg/g gel from GlaxoSmithKline Dungarvan Limited.
The product is indicated for the relief of pain, inflammation and swelling in soft-tissue injuries, localised forms of soft tissue rheumatism, and for the relief of pain of non-serious arthritis of the knee or fingers.
A comprehensive description of the indications and posology is given in the SmPC.

The marketing authorisation has been granted pursuant to Article 8(3) of Directive 2001/83/EC.

The drug product is a line extension to Voltaren Emulgel, 11.6 mg/g gel (addition of a new strength).

II. QUALITY ASPECTS

II.1 Introduction

Voltaren Emulgel gel is a topical dosage form containing 23.2 mg/g of diclofenac diethylamine.
The excipients are butylhydroxytoluene (E321), carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, oleyl alcohol, perfume eucalyptus sting, propylene glycol and purified water. The finished product is a white to practically white, soft, homogenous, cream-like gel. The gel is packed in Aluminum laminated tube (from outside to inside: low density polyethylene, aluminum, high density polyethylene) with a shoulder and membrane made of high density polyethylene and a screw cap made of polypropylene.

II.2 Drug Substance

Diclofenac sodium is a non-steroidal anti-inflammatory agent (NSAID). The drug substance is white to light beige crystalline powder. Diclofenac diethylamine does not possess chiral centers. Also no polymorphic forms have been observed.
The route of synthesis has been adequately described and satisfactory specifications have been provided for starting material, reagents and solvents. The active substance specification includes relevant tests and the limits for impurities have been justified. The analytical methods applied are suitably described and validated.
Stability studies under ICH conditions have been conducted and the data provided are sufficient to confirm the retest period.

II.3 Medicinal Product

Emulgel gel is a topical dosage form containing 23.2 mg/g of diclofenac diethylamine that corresponds to 20 mg/g of diclofenac sodium.
The finished product is white to practically white, soft, homogenous, cream-like gel.
The development of the product has been described. The manufacturing process was developed based on the existing well established process used for the manufacture of Voltaren Emulgel 11.6 mg/g gel.
The choice of excipients is justified and their functions explained.

The information provided with regard to manufacturing process of the medicinal product is considered adequate.
The drug product specifications are considered acceptable. The analytical methods are described and validated. Batch analysis has been provided for 6 bulk batches, for 5 batches of 20 g laminated tubes and for 4 batches of 100 g laminated tubes.
The gel is packed in PE/Al/PE laminated tube (from outside to inside: low density polyethylene, aluminium, high density polyethylene) with shoulder and membrane made of high density polyethylene and screw cap made of polypropylene.
The conditions used in the stability studies are according to the ICH guideline. The proposed shelf-life of 36 months with no additional storage statement required for the product packaged in the proposed configuration.

III. NON-CLINICAL ASPECTS

III.1 Ecotoxicity/environmental risk assessment (ERA)

The applicant has submitted an environmental risk assessment. The PEC surface water of diclofenac resulting from use of DDEA 2.32% gel is 0.93 μg/l. An assessment factor of 10 and NOEC from the most sensitive of the species tested in chronic toxicity tests are used to compute the PNEC. The PEC/PNEC ratio obtained for the active ingredient, diclofenac is less than 1 and show that usage of DDEA 2.32% gel is unlikely to represent a risk to the aquatic environment. Diclofenac has no significant bioaccumulation potential and is degraded slowly in the environment. Exposure to sunlight was observed to increase its degradation. The use of DDEA 2.32% gel as a human medicinal product is not likely to represent a significant environmental safety risk.

III.2 Discussion on the non-clinical aspects

This product is a line extension to the existing Voltaren Emulgel 11.6 mg/g (1.16%) gel. Pharmacodynamic, pharmacokinetic and toxicological properties of diclofenac are well known. As diclofenac is a widely used, well-known active substance, the applicant has not provided additional studies and further studies are not required.

IV. CLINICAL ASPECTS

IV.1 Introduction

The preparation containing diclofenac diethylamine 23.2 mg/g (2.32%) gel is a topical NSAID agent which has been developed as a higher-strength formulation of the well known globally marketed diclofenac diethylamine 1.16% gel and is intended for the same indication as the marketed product diglofenac diethylamine 1.16% gel, *i.e.* for the relief of pain, inflammation and swelling of soft-tissue injuries.
Diclofenac is a well-known, potent, NSAID with analgesic, anti-inflammatory and antipyretic properties. Inhibition of prostaglandin synthesis is the primary mechanism of action of diclofenac. Prostaglandins are mediators of pain and inflammation resulting from soft tissue (muscle and joint) injuries. With topical administration of diclofenac gel, a high concentration of diclofenac can be achieved in the inflamed tissue without significant concentration in the plasma, minimising the risk of systemic adverse effects.

IV.2 Discussion on the clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to clinical efficacy/safety, no further such data have been submitted or are considered necessary.

V. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

User consultation

A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to the product of the Voltaren Emulgel, which contains diclofenac (as diclofenac diethylamine) at a strength of 1.16%. The bridging report submitted by the applicant has been found acceptable.

The risk/benefit ratio is considered positive and the application for Voltaren Emulgel 23.2 mg/g (2.32%) gel product is recommended for approval.